Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Health Sciences Authority
HSA Updates

Withdrawal of Pholcodine-Containing Medicines in Singapore

Audiences

Consumer

Healthcare professional

Industry member

Product type

Therapeutic Products

22 June 2023

This article has been migrated from an earlier version of the site and may display formatting inconsistencies.

The Health Sciences Authority (HSA) would like to inform the public that all pholcodine-containing medicines will be withdrawn in Singapore. The company marketing these products, iNova Pharmaceuticals (Singapore) Pte Ltd, is cancelling the registrations of these pholcodine-containing medicines and ceasing their supply in the local market. This is a precautionary measure due to overseas findings of a rare and very small risk of severe allergic reactions (i.e., anaphylaxis) to muscle relaxants (neuromuscular blocking agents or NMBAs) used during general anaesthesia in patients who have taken pholcodine, particularly in the preceding 12 months.

2        Pholcodine is one of several medicines used to treat dry cough. In Singapore, pholcodine-containing medicines have been registered since 1993 as pharmacy-only medicines and can only be obtained from healthcare professionals, such as doctors and pharmacists. Please see Annex A for the list of seven pholcodine-containing medicine registered in Singapore.

3        A safety study (ALPHO study[1]) conducted in France found that there is a link between pholcodine and an increased risk of anaphylaxis with NMBAs used during general anaesthesia in surgeries. This safety risk is rare and assessed to be very low. To date, HSA has not received any local reports of NMBA-related anaphylactic reactions suspected to be associated with pholcodine.

4        HSA has conducted a review of the study and other available safety data and considered whether there are effective measures that can be taken to mitigate this safety risk. In consultation with medical experts from its Product Vigilance Advisory Committee, HSA has concluded that the potential risks outweigh the benefits of these products, and pholcodine-containing medicines should be withdrawn from the local market as a precautionary measure.

Patient advisory

5        Patients are advised on the following:

  • If you are undergoing surgery involving the use of general anaesthesia and had taken any pholcodine-containing medicines, particularly in the past 12 months, inform your anaesthetist or doctor. The risk of anaphylaxis during surgeries is very rare. Anaesthetists are well trained to manage anaphylaxis and will take this into consideration during your surgery.

  • Consult your doctor or pharmacist if you have any questions or concerns on the pholcodine-containing medicines you are taking or for advice on alternative treatments for dry cough.

HEALTH SCIENCES AUTHORITY
SINGAPORE
22 JUNE 2023

Download PDF version here [PDF, 131 KB]

[1] https://www.bjanaesthesia.org/article/S0007-0912(23)00104-6/fulltext

Back to top